{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:40:25Z","timestamp":1793194825325,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.rmed.2018.06.026","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T05:54:32Z","timestamp":1530338072000},"page":"72-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma"],"prefix":"10.1016","volume":"141","author":[{"given":"Fausto","family":"Petrelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Ardito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Coinu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Cabiddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Ghilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Borgonovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Barni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ghidini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rmed.2018.06.026_bib1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.1996.14.3.1007","article-title":"Chemotherapy in malignant pleural mesothelioma: a review","volume":"14","author":"Ong","year":"1996","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.rmed.2018.06.026_bib2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"10026","key":"10.1016\/j.rmed.2018.06.026_bib3","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.rmed.2018.06.026_bib4","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"7414","key":"10.1016\/j.rmed.2018.06.026_bib5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ Br. Med. J. (Clin. Res. Ed.)"},{"issue":"4","key":"10.1016\/j.rmed.2018.06.026_bib6","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias author ( s ): Colin B. Begg and Madhuchhanda Mazumdar published by\u202f: international Biometric society stable","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"issue":"7129","key":"10.1016\/j.rmed.2018.06.026_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.316.7129.469","article-title":"Bias in meta-analysis detected by a simple, graphical","volume":"316","author":"Stuck","year":"1998","journal-title":"Br. Med. J."},{"key":"10.1016\/j.rmed.2018.06.026_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/jrsm.1260","article-title":"Introduction, Comparison, and Validation of Meta-Essentials\u202f: a free and simple tool for meta-analysis","author":"Suurmond","year":"2017","journal-title":"Res. Synth. Meth."},{"issue":"3","key":"10.1016\/j.rmed.2018.06.026_bib9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.lungcan.2013.11.011","article-title":"Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"84","author":"Zucali","year":"2014","journal-title":"Lung Canc."},{"issue":"3","key":"10.1016\/j.rmed.2018.06.026_bib10","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.lungcan.2011.08.011","article-title":"Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey","volume":"75","author":"Zucali","year":"2012","journal-title":"Lung Canc."},{"issue":"7","key":"10.1016\/j.rmed.2018.06.026_bib11","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1002\/cncr.23337","article-title":"Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma","volume":"112","author":"Zucali","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.rmed.2018.06.026_bib12","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.lungcan.2014.03.006","article-title":"Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma","volume":"84","author":"Zauderer","year":"2014","journal-title":"Lung Canc."},{"issue":"4","key":"10.1016\/j.rmed.2018.06.026_bib13","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10147-013-0619-5","article-title":"Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy","volume":"19","author":"Toyokawa","year":"2014","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.rmed.2018.06.026_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1745-6673-3-34","article-title":"Gemcitabine combined with oxaliplatin in pretreated patients with malignant pleural mesothelioma: an observational study","volume":"3","author":"Xanthopoulos","year":"2008","journal-title":"J. Occup. Med. Toxicol."},{"issue":"11","key":"10.1016\/j.rmed.2018.06.026_bib15","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.jtho.2016.06.024","article-title":"A phase II study of PF-03446962 in patients with advanced malignant pleural mesothelioma. CCTG trial IND.207","volume":"11","author":"Wheatley-Price","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.rmed.2018.06.026_bib16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.rmed.2018.06.026_bib17","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clon.2010.01.009","article-title":"Life after first-line chemotherapy in malignant pleural mesothelioma: a north-east england experience","volume":"22","author":"Steer","year":"2010","journal-title":"Clin. Oncol."},{"issue":"1","key":"10.1016\/j.rmed.2018.06.026_bib18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.lungcan.2008.04.001","article-title":"The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma","volume":"63","author":"Stebbing","year":"2009","journal-title":"Lung Canc."},{"issue":"1","key":"10.1016\/j.rmed.2018.06.026_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/COC.0b013e3181cae90e","article-title":"Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma","volume":"34","author":"Tourkantonis","year":"2011","journal-title":"Am. J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.rmed.2018.06.026_bib20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.rmed.2009.07.019","article-title":"Pemetrexed in the treatment of malignant mesothelioma: results from an expanded access program in Germany","volume":"104","author":"Reck","year":"2010","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2018.06.026_bib21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1186\/s12885-015-1881-x","article-title":"Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)","volume":"15","author":"Raynaud","year":"2015","journal-title":"BMC Canc."},{"issue":"7","key":"10.1016\/j.rmed.2018.06.026_bib22","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/JTO.0b013e31817c73d6","article-title":"Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemona\u00efve patients with malignant pleural mesothelioma: results of the international expanded access program","volume":"3","author":"Santoro","year":"2008","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.rmed.2018.06.026_bib23","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/JTO.0b013e31802f3813","article-title":"Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment","volume":"2","author":"S\u00f8rensen","year":"2007","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.rmed.2018.06.026_bib24","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-Containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.rmed.2018.06.026_bib25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.lungcan.2011.01.005","article-title":"Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience","volume":"73","author":"Pasello","year":"2011","journal-title":"Lung Canc."},{"issue":"1","key":"10.1016\/j.rmed.2018.06.026_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","article-title":"Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma","volume":"4","author":"Ramalingam","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.rmed.2018.06.026_bib27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.lungcan.2004.11.015","article-title":"Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients","volume":"48","author":"Porta","year":"2005","journal-title":"Lung Canc."},{"issue":"8","key":"10.1016\/j.rmed.2018.06.026_bib28","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-014-0074-9","article-title":"Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study","volume":"31","author":"Mutlu","year":"2014","journal-title":"Med. Oncol."},{"issue":"9","key":"10.1016\/j.rmed.2018.06.026_bib29","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1097\/JTO.0b013e31825f22ee","article-title":"A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma","volume":"7","author":"Nowak","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"6","key":"10.1016\/j.rmed.2018.06.026_bib30","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/annonc\/mdi187","article-title":"Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma","volume":"16","author":"Manegold","year":"2005","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.rmed.2018.06.026_bib31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1097\/01243894-200607000-00002","article-title":"Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program","volume":"1","author":"Janne","year":"2006","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.rmed.2018.06.026_bib32","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.23617","article-title":"Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma","volume":"113","author":"Jackman","year":"2008","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.rmed.2018.06.026_bib33","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.lungcan.2013.05.006","article-title":"A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced malignant pleural mesothelioma","volume":"81","author":"Nowak","year":"2013","journal-title":"Lung Canc."},{"issue":"4","key":"10.1016\/j.rmed.2018.06.026_bib34","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S1470-2045(15)70056-2","article-title":"Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"16","author":"Krug","year":"2015","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.rmed.2018.06.026_bib35","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/ejcts\/ezv398","article-title":"Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma","volume":"49","author":"Kostron","year":"2016","journal-title":"Eur J Cardio-thoracic Surg"},{"issue":"11","key":"10.1016\/j.rmed.2018.06.026_bib36","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/JTO.0b013e3182333df5","article-title":"Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC clinical trials group","volume":"6","author":"Laurie","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"Suppl 8","key":"10.1016\/j.rmed.2018.06.026_bib37","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0959-8049(02)80018-1","article-title":"Phase II trial of ZD0473 as second-line therapy in mesothelioma","volume":"38","author":"Giaccone","year":"2002","journal-title":"Eur. J. Canc."},{"key":"10.1016\/j.rmed.2018.06.026_bib38","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","author":"Maio","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.rmed.2018.06.026_bib39","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2016.12.004","article-title":"A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group","volume":"104","author":"Laurie","year":"2017","journal-title":"Lung Canc."},{"issue":"11","key":"10.1016\/j.rmed.2018.06.026_bib40","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1097\/JTO.0b013e318229586e","article-title":"Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509","volume":"6","author":"Garland","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"20","key":"10.1016\/j.rmed.2018.06.026_bib41","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.7314\/APJCP.2014.15.20.8843","article-title":"Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma","volume":"15","author":"Gunduz","year":"2014","journal-title":"Asian Pac. J. Cancer Prev. APJCP"},{"issue":"15","key":"10.1016\/j.rmed.2018.06.026_bib42","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2009.27.3649","article-title":"Phase II study of asparagine-glycine-arginine-human tumor necrosis factor \u03b1, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma","volume":"28","author":"Gregorc","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.rmed.2018.06.026_bib43","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.rmed.2018.06.026_bib44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/JTO.0b013e318248242c","article-title":"Phase II study of dasatinib in patients with previously treated malignant mesothelioma (cancer and leukemia group B 30601): a Brief report","volume":"7","author":"Dudek","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.rmed.2018.06.026_bib45","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1097\/JTO.0b013e318260dfb9","article-title":"Phase II clinical trial of first or second-line treatment with Bortezomib in patients with malignant pleural mesothelioma","volume":"7","author":"Fennell","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.rmed.2018.06.026_bib46","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/cncr.22366","article-title":"Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma","volume":"109","author":"Fennell","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.rmed.2018.06.026_bib47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2012.06.011","article-title":"Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium","volume":"78","author":"Campbell","year":"2012","journal-title":"Lung Canc."},{"issue":"10","key":"10.1016\/j.rmed.2018.06.026_bib48","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s12032-014-0232-0","article-title":"The clinicopathological characteristics with long-term outcomes in malignant mesothelioma","volume":"31","author":"Dogan","year":"2014","journal-title":"Med. Oncol."},{"issue":"1","key":"10.1016\/j.rmed.2018.06.026_bib49","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Canc."},{"issue":"4","key":"10.1016\/j.rmed.2018.06.026_bib50","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabr\u00f2","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.rmed.2018.06.026_bib51","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.rmed.2018.06.026_bib52","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/1756-0500-5-482","article-title":"Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience","volume":"5","author":"Bearz","year":"2012","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.rmed.2018.06.026_bib53","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/CLEP.S105396","article-title":"Mesothelioma in the United States: a surveillance, epidemiology, and end results (SEER)\u2013medicare investigation of treatment patterns and overall survival","volume":"8","author":"Beebe-Dimmer","year":"2016","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.rmed.2018.06.026_bib54","first-page":"825","article-title":"Malignant pleural mesothelioma: a single-center experience in Turkey","volume":"20","author":"\u00d6zy\u0131lkan","year":"2014","journal-title":"Med. Sci. Mon. Int. Med. J. Exp. Clin. Res."},{"issue":"1","key":"10.1016\/j.rmed.2018.06.026_bib55","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.00037310","article-title":"Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study","volume":"37","author":"Scherpereel","year":"2011","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2018.06.026_bib56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.critrevonc.2016.05.004","article-title":"The third Italian Consensus Conference for malignant pleural mesothelioma: state of the art and recommendations","volume":"104","author":"Novello","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.rmed.2018.06.026_bib57","doi-asserted-by":"crossref","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.rmed.2018.06.026_bib58","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1470-2045(18)30100-1","article-title":"Novel therapies for malignant pleural mesothelioma","volume":"19","author":"Scherpereel","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.rmed.2018.06.026_bib59","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jtho.2017.09.1968","article-title":"Molecular and histopathological Characterization of the tumor immune Microenvironment in advanced stage of malignant pleural mesothelioma","volume":"13","author":"Patil","year":"2018","journal-title":"J. Thorac. Oncol."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118302245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611118302245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T11:42:12Z","timestamp":1760614932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611118302245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":59,"alternative-id":["S0954611118302245"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2018.06.026","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2018.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}